HIV Infection Clinical Trial
Official title:
Gene Therapy for AIDS Using Retroviral Mediated Gene Transfer to Deliver HIV-1 Anti-Sense TAR and Transdominant Rev Protein Genes to Syngeneic Lymphocytes in HIV-1 Infected Identical Twins
This study will test the safety and effectiveness of genetically altered T lymphocytes
(white blood cells of the immune system) in reducing viral load in patients infected with
the human immunodeficiency virus (HIV). The lymphocytes will have two genes inserted into
them; a laboratory-manufactured anti-HIV gene designed to inhibit HIV reproduction (either
the RevTD or Rev-TD-antiTAR gene), and a "marker" gene that will show whether or not the
inserted genes have gotten into the cells.
Identical twin pairs 18 years of age and older- one of whom is HIV-positive (infected with
the human immunodeficiency virus) and the other HIV-negative (not infected) may be eligible
for this study.
All participants will have a complete medical history and physical examination, blood tests
and a tetanus booster shot, if indicated. The non HIV-infected twin will then undergo
lymphapheresis to collect lymphocytes. In this procedure, whole blood is collected through a
needle placed in an arm vein. The blood circulates through a machine that separates it into
its components. The lymphocytes are then removed, and the red cells and plasma are returned
to the donor, either through the same needle or through a second needle placed in the other
arm.
The donor cells are grown in the laboratory for a few days, and then the new genes are
inserted into them. The genetically altered cells are grown in the laboratory for several
days until their numbers increase approximately a thousand-fold. They are then infused
intravenously (through a vein) into the infected twin. These procedures-lymphapheresis, gene
modification and infusion-will be repeated at approximately 2-month intervals up to four
times.
Each lymphocyte infusion takes about 60 minutes. The patient's vital signs (temperature,
pulse, blood pressure and breathing) are monitored frequently during the infusion and hourly
for 4 hours after the infusion. Blood samples are taken the day of the infusion, 3 days
later, and then weekly to monitor the gene-modified cells, immune status, viral activity,
and other factors. These tests may be done less often as the study progresses and more is
learned about the safety of the infusions. The infusions are done on an outpatient basis
unless side effects require that they be done in the hospital with post-infusion monitoring
for at least 24 hours.
Patients will be followed for long-term effects of treatment monthly for the first 3 months,
once a month for the next 9 months and yearly from then on.
This study will contribute information about the use and side effects of gene therapy in HIV
infection that may lead to new treatment strategies. A potential direct benefit to
HIV-infected individuals participating in this study is reduced viral load; in laboratory
studies, the RevTD and Rev-TD-antiTAR genes have inhibited HIV spread in the test tube.
However, this is an early phase of study, and the likelihood of receiving this benefit is
unknown.
This phase I/II pilot study will evaluate the safety, relative survival, and potential efficacy of infusions of activated, genetically engineered, syngeneic CD4+ T lymphocytes obtained from HIV-1 seronegative identical twins. T cells from each seronegative twin will be obtained by apheresis, enriched for CD4+ cells, induced to polyclonal proliferation with anti-CD3 and rIL-2 stimulation, divided into aliquots which will then be individually transduced with a control retroviral vector and up to two additional retroviral vectors containing potentially therapeutic genes (antisense TAR and/or transdominant Rev). These engineered T cell populations will be expanded 10-1,000 fold in numbers during 1-2 weeks of culture, and then will be infused into the seropositive twins. The relative survival of the uniquely engineered T cell populations will be monitored by vector-specific PCR, while the recipients' functional immune status is monitored by standard in vitro and in vivo testing protocols. A total of up to 4 cycles of treatment may be given using identical or different combinations of control and anti-HIV-1 retroviral vectors. ;
Endpoint Classification: Safety Study, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT02135419 -
Treatment in Preventing Anal Cancer in Patients With HIV and Anal High-Grade Lesions
|
Phase 3 | |
Active, not recruiting |
NCT02663856 -
My Smart Age With HIV: Smartphone Self-assessment of Frailty
|
||
Terminated |
NCT02743598 -
Liraglutide for HIV-associated Neurocognitive Disorder
|
Phase 4 | |
Completed |
NCT02663869 -
Aging With HIV at Younger vs Older Age: a Diverse Population With Distinct Comorbidity Profiles
|
||
Completed |
NCT02921516 -
Growing Up: Intervening With HIV-Positive Adolescents in Resource-Poor Settings
|
N/A | |
Completed |
NCT02659306 -
Metformin Immunotherapy in HIV Infection
|
Phase 1 | |
Completed |
NCT02846402 -
Impact of HIV Self-testing Among Female Sex Workers in Kampala, Uganda
|
N/A | |
Completed |
NCT02564341 -
Targeting Effective Analgesia in Clinics for HIV - Intervention
|
N/A | |
Active, not recruiting |
NCT02302950 -
A Retrospective Analysis of Raltegravir Use in Minority HIV Infected Women in Houston, Texas
|
N/A | |
Completed |
NCT01830595 -
Lactoferrin Treatment in HIV Patients
|
Phase 2 | |
Completed |
NCT02269605 -
Bryostatin-1 Effect on HIV-1 Latency and Reservoir in HIV-1 Infected Patients Receiving Antiretroviral Treatment
|
Phase 1 | |
Terminated |
NCT02109224 -
Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection
|
Phase 1 | |
Completed |
NCT01852942 -
Reversing Tissue Fibrosis to Improve Immune Reconstitution in HIV
|
Phase 2 | |
Terminated |
NCT01902186 -
Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
|
Phase 4 | |
Completed |
NCT02118168 -
Observational Study for the Extended Follow-up of the Patients Enrolled in the Therapeutic Clinical Trial ISS T-002
|
N/A | |
Completed |
NCT02525146 -
Birmingham Access to Care Study
|
N/A | |
Completed |
NCT02527135 -
Text Messaging to Improve HIV Testing Among Young Women in Kenya
|
N/A | |
Completed |
NCT01946217 -
Factors Affecting Patient Participation in AIDS Malignancy Clinical Trials Consortium Clinical Trials
|
N/A | |
Active, not recruiting |
NCT02602418 -
Neural Correlates of Working Memory Training for HIV Patients
|
N/A | |
Completed |
NCT01680094 -
Safety and Effect of The HDAC Inhibitor Panobinostat on HIV-1 Expression in Patients on Suppressive HAART
|
Phase 1/Phase 2 |